Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 5/20 | 0.94 |
| ▸ | CCR8 | P51685 | 5/20 | 0.94 |
| ▸ | LMNA | P02545 | 4/20 | 0.94 |
| ▸ | CCR5 | P51681 | 3/20 | 0.94 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.94 |
| ▸ | MMP2 | P08253 | 2/20 | 0.94 |
| ▸ | TSHR | P16473 | 2/20 | 0.94 |
| ▸ | MAPT | P10636 | 2/20 | 0.94 |
| ▸ | HTT | P42858 | 2/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.94 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.94 |
| ▸ | GMNN | O75496 | 1/20 | 0.94 |
| ▸ | TP53 | P04637 | 1/20 | 0.94 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.94 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.94 |
| ▸ | MMP9 | P14780 | 1/20 | 0.94 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.94 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.94 |
| ▸ | MMP8 | P22894 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenanthroline SCHEMBL30868492 | 1.00 | CCR1 (0.94) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL11542337 | 0.97 | CCR1 (0.89) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL29367277 | 0.97 | CCR1 (1.00) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL29354015 | 0.97 | CCR1 (1.00) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL8845760 | 0.97 | CCR1 (1.00) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL8312 | 0.97 | CCR1 (1.00) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL22982126 | 0.94 | CCR1 (0.94) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL21044608 | 0.94 | CCR1 (0.94) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL21060516 | 0.94 | CCR1 (0.94) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL21300488 | 0.94 | CCR1 (0.94) | CCR1CCR8LMNACCR5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689598-A1 | MOTION BASED DYNAMIC TENSIOMETER FOR DETECTING THE PRESENCE OF SURFACTANTS | Ecolab USA Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| WO-2025193253-A9 | GENERATING BRONSTED ACID CATALYSTS BY ELECTRICAL POLARIZATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-12-26 | — | — | WO | claimed |
| WO-2024205687-A1 | MOTION BASED DYNAMIC TENSIOMETER FOR DETECTING THE PRESENCE OF SURFACTANTS | ECOLAB USA INC. (US) | 2024-10-03 | — | — | WO | claimed |
| US-20240328959-A1 | MOTION BASED DYNAMIC TENSIOMETER FOR DETECTING THE PRESENCE OF SURFACTANTS | ECOLAB USA INC. | 2024-10-03 | — | — | US | claimed |
| CN-117070983-A | Fe-N-C supported gamma-Fe 2 O 3 Catalyst of hollow sphere material, preparation method and application thereof | 合肥工业大学 | 2023-11-17 | — | — | CN | claimed |
| WO-2023092210-A1 | METHOD AND DEVICE FOR AMPLIFYING TRANSDUCER SIGNALS FOR CAPACITIVE ASSAYS | UNIVERSIDADE ESTADUAL PAULISTA JULIO DE MESQUITA FILHO (BR) | 2023-06-01 | — | — | WO | claimed |
| CN-113937248-B | Preparation method of removable/embeddable alkali metal ion material | 中国科学院宁波材料技术与工程研究所 | 2023-05-09 | — | — | CN | claimed |
| WO-2022084158-A1 | METHOD FOR OXIDIZING 5-HYDROXYMETHYLFURFURAL | IFP Energies Nouvelles (FR) | 2022-04-28 | — | — | WO | claimed |
| CN-114292413-A | Preparation method and application of self-repairing material based on aromatic carboxylic acids MOFs | 贵州乌江水电开发有限责任公司思林发电厂 | 2022-04-08 | — | — | CN | claimed |
| CN-117126331-B | Preparation method and application of polyacrylamide monoatomic oxygen reduction catalyst | 华侨大学 | 2026-04-28 | — | — | CN | disclosed |
| US-12605373-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-21 | — | — | US | disclosed |
| US-12589111-B2 | Pt(IV) chemotherapeutic prodrug and controlled release thereof for treatment of tumors | PEKING UNIVERSITY (CN) | 2026-03-31 | — | — | US | disclosed |
| US-12577581-B2 | Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells | CELLECTIS (FR) | 2026-03-17 | — | — | US | disclosed |
| EP-4705765-A2 | BUCCAL CELL DIAGNOSIS OF RISK IN FAMILIAL ARRHYTHMIA SYNDROMES | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-11274294-B2 | TAL effector-mediated DNA modification | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-03-15 | — | — | US | disclosed |
| US-11274316-B2 | Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells | CELLECTIS (FR) | 2022-03-15 | — | — | US | disclosed |
| EP-3964567-A1 | METHODS FOR ENGINEERING ALLOGENEIC AND IMMUNOSUPPRESSIVE RESISTANT T CELL FOR IMMUNOTHERAPY | Cellectis (FR) | 2022-03-09 | — | — | EP | disclosed |
| US-20220056482-A1 | METHODS FOR MAKING GENETIC EDITS | URUS GROUP LP | 2022-02-24 | — | — | US | disclosed |
| EP-3948993-A1 | PROCESS FOR CRUSHING AN ELECTROCHEMICAL GENERATOR | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2022-02-09 | — | — | EP | disclosed |
| EP-3948994-A1 | METHOD FOR NEUTRALIZING AN ELECTROCHEMICAL GENERATOR | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605373-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | CUL3, CUL1, CUL5 | CCR1 621/4885CCR8 1727/4885LMNA 1190/4885 |
| US-12577581-B2 | Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells | PBK, CD22, CD2 | CCR1 831/4885CCR8 820/4885LMNA 537/4885 |
| US-12589111-B2 | Pt(IV) chemotherapeutic prodrug and controlled release thereof for treatment of tumors | PTGER4, PTGDR, PTGER3 | CCR1 1717/4885CCR8 481/4885LMNA 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.